Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Steinberg

Showing results (1031-1040 of 1,520) with videos related to

Pageof 152
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2Christina M Annunziata, Amanda J Walker, Lori Minasian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 1999
A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancerK S Bauer, W D Figg, J M Hamilton, et al.
American Journal of Clinical Oncology|June 1, 2002
Phase II neoadjuvant trial of paclitaxel by 96-hour continuous infusion (CIVI) in combination with cisplatin followed by chest radiotherapy for patients with stage III non-small-cell lung cancerO S Breathnach, V Kasturi, F Kaye, et al.
Annals of Surgical Oncology|July 29, 2018
An Examination of Applicants and Factors Associated with Matriculation to Complex General Surgical Oncology Fellowship Training ProgramsMichael M Wach, Samantha M Ruff, Reed I Ayabe, et al.
Cancer|March 3, 2007
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancerEdwin M Posadas, Meghan S Liel, Virginia Kwitkowski, et al.
Investigational New Drugs|August 26, 2006
Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancerNeelima Denduluri, James J Lee, Janice Walshe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a phase I trial in patients with advanced lung cancerM S Georgiadis, B S Schuler, J E Brown, et al.
American Journal of Surgery|January 20, 2016
Significance of preoperative radiographic pancreatic density in predicting pancreatic fistula after surgery for pancreatic neuroendocrine tumorsYasmine Assadipour, Saïd C Azoury, Nicholas N Schaub, et al.
JTO Clinical and Research Reports|October 18, 2021
Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in <i>BAP1</i> GeneAzam Ghafoor, Idrees Mian, Cathy Wagner, et al.
Critical Care (London, England)|February 17, 2007
Effect of positive end-expiratory pressure and tidal volume on lung injury induced by alveolar instabilityJeffrey M Halter, Jay M Steinberg, Louis A Gatto, et al.
Pageof 152

Showing results (1031-1040 of 1,520) with videos related to

Sort By:
Pageof 152
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2Christina M Annunziata, Amanda J Walker, Lori Minasian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 1999
A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancerK S Bauer, W D Figg, J M Hamilton, et al.
American Journal of Clinical Oncology|June 1, 2002
Phase II neoadjuvant trial of paclitaxel by 96-hour continuous infusion (CIVI) in combination with cisplatin followed by chest radiotherapy for patients with stage III non-small-cell lung cancerO S Breathnach, V Kasturi, F Kaye, et al.
Annals of Surgical Oncology|July 29, 2018
An Examination of Applicants and Factors Associated with Matriculation to Complex General Surgical Oncology Fellowship Training ProgramsMichael M Wach, Samantha M Ruff, Reed I Ayabe, et al.
Cancer|March 3, 2007
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancerEdwin M Posadas, Meghan S Liel, Virginia Kwitkowski, et al.
Investigational New Drugs|August 26, 2006
Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancerNeelima Denduluri, James J Lee, Janice Walshe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a phase I trial in patients with advanced lung cancerM S Georgiadis, B S Schuler, J E Brown, et al.
American Journal of Surgery|January 20, 2016
Significance of preoperative radiographic pancreatic density in predicting pancreatic fistula after surgery for pancreatic neuroendocrine tumorsYasmine Assadipour, Saïd C Azoury, Nicholas N Schaub, et al.
JTO Clinical and Research Reports|October 18, 2021
Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in <i>BAP1</i> GeneAzam Ghafoor, Idrees Mian, Cathy Wagner, et al.
Critical Care (London, England)|February 17, 2007
Effect of positive end-expiratory pressure and tidal volume on lung injury induced by alveolar instabilityJeffrey M Halter, Jay M Steinberg, Louis A Gatto, et al.
Pageof 152